These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7983239)

  • 1. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator.
    Matsui D; Hermann C; Klein J; Berkovitch M; Olivieri N; Koren G
    J Clin Pharmacol; 1994 Sep; 34(9):944-9. PubMed ID: 7983239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance assessed by the Medication Event Monitoring System.
    Olivieri NF; Matsui D; Hermann C; Koren G
    Arch Dis Child; 1991 Dec; 66(12):1399-402. PubMed ID: 1776885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
    Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
    Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
    Olivieri NF; Brittenham GM; Matsui D; Berkovitch M; Blendis LM; Cameron RG; McClelland RA; Liu PP; Templeton DM; Koren G
    N Engl J Med; 1995 Apr; 332(14):918-22. PubMed ID: 7877649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
    Collins AF; Fassos FF; Stobie S; Lewis N; Shaw D; Fry M; Templeton DM; McClelland RA; Koren G; Olivieri NF
    Blood; 1994 Apr; 83(8):2329-33. PubMed ID: 8161801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
    al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
    Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia.
    Matsui D; Klein J; Hermann C; Grunau V; McClelland R; Chung D; St-Louis P; Olivieri N; Koren G
    Clin Pharmacol Ther; 1991 Sep; 50(3):294-8. PubMed ID: 1914364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.
    Agarwal MB; Gupte SS; Viswanathan C; Vasandani D; Ramanathan J; Desai N; Puniyani RR; Chhablani AT
    Br J Haematol; 1992 Oct; 82(2):460-6. PubMed ID: 1419829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
    al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
    J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
    Kontoghiorghes GJ; Bartlett AN; Sheppard L; Barr J; Nortey P
    Arzneimittelforschung; 1995 Jan; 45(1):65-9. PubMed ID: 7893273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
    al-Refaie FN; Wickens DG; Wonke B; Kontoghiorghes GJ; Hoffbrand AV
    Br J Haematol; 1992 Oct; 82(2):431-6. PubMed ID: 1419825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia.
    Olivieri NF; Koren G; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM
    Blood; 1992 May; 79(10):2741-8. PubMed ID: 1586721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K; Pyar K; Wonke B
    Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-center safety trial of the oral iron chelator deferiprone.
    Cohen A; Galanello R; Piga A; Vullo C; Tricta F
    Ann N Y Acad Sci; 1998 Jun; 850():223-6. PubMed ID: 9668543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
    Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
    Olivieri NF; Templeton DM; Koren G; Chung D; Hermann C; Freedman MH; McClelland RA
    Ann N Y Acad Sci; 1990; 612():369-77. PubMed ID: 2291564
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
    Olivieri NF; Koren G; Hermann C; Bentur Y; Chung D; Klein J; St Louis P; Freedman MH; McClelland RA; Templeton DM
    Lancet; 1990 Nov; 336(8726):1275-9. PubMed ID: 1978115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
    Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV; Goddard JG; Sheppard L; Barr J; Nortey P
    Br J Haematol; 1990 Oct; 76(2):295-300. PubMed ID: 2094333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.